研發策略 Strategy

百靈佳殷格翰的研發策略旨在進一步提高我們的創新能力，並激發更多解決疾病問題的創新。

四大治療研究領域
在藥品與解決方案的各階段，如從早期研究推展到臨床試驗，再到市場進入…等，透過持續關注已累積專業知識的疾病類別來強化研發優勢。

創造並提供研發平台
專注於高度動態發展的研究領域，如免疫調節和再生醫學，藉此引動我們的幾個研究治療領域間的協同作用。

無限際研發
探索新興科學技術，跨越現有研究治療範疇，以便即時並有效地進入全新的醫療和科學領域與技術。

Our new discovery research strategy aims at further enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need. It is based on three pillars:

Four Discovery Research Therapeutic Areas
Build on our strengths in R&D by focusing on core diseases for which we have built expertise over time and are actively investing from early research, through clinical development, to the market phase.

Scientific platforms
Focus on highly dynamic research fields such as immune modulation and regenerative medicine which may impact and create synergies among several of our Discovery Research Therapeutic Areas.

Research Beyond Borders
Explore emerging science and technology for but also beyond our Discovery Research Therapeutic Areas in order to prepare a timely and efficient entry into emerging new medical and scientific fields and technologies.


中樞神經系統疾病研究 Central Nervous System Diseases Research

人類比以往更了解大腦的運作，但我們仍然缺乏真正改善精神疾病患者生活品質的治療方法，發現新的途徑來發展可有效降低精神疾病症狀治療的方法仍是迫切的需求！目前，我們的研發往兩個層次前進，一是更系統化的了解大腦負責部位與各精神疾病症狀的關聯性，二是開發針對已知關聯的治療方法。

我們相信透過更認識大腦將會引發一系列疾病治療方法的發展，更進而改善患者的生活品質。而以病患生活品質改善為目標，我們也將更具潛能來為阿茨海默症，精神分裂症和憂鬱症患者來產生更多價值。

目前，我們有超過200名科學家在德國比拉貝的中樞神經系統藥物研發中心工作。
我們研發的重點是:

  • 精神疾病
    • 精神分裂症
    • 憂鬱症
  • 阿茨海默症（認知）

We know more than ever about the workings of the brain, yet we still lack treatments that truly improve the lives of people with mental illness. A new approach is needed to discover and develop treatments that will reduce the impact of the worst symptoms of mental illness. Our approach is twofold, we identify brain malfunctions responsible for key symptoms present in a range of mental disorders, and we research and develop targeted treatments for those.

We are confident that identifying and treating the underlying brain malfunctions responsible for major symptoms such as cognitive impairment, across a range of diseases, will bring the treatments needed to improve life for people with mental illness. By having the real-life experience of patients’ front of mind, our research has the potential to significantly improve the lives of people living with Alzheimer’s disease, schizophrenia and depression.

More than 200 scientists work at our fully integrated CNS drug discovery centre in Biberach, Germany. 
Our Discovery Research focus is on:

  • Psychiatric diseases
    • Schizophrenia
    • Depression 
  • Alzheimer’s disease  (cognition)